Hosted on MSN1mon
Ozempic maker Novo Nordisk, after trial disappointment, expands AI deal in potential $4.6 billion pactOzempic weight-loss drug maker Novo Nordisk on Wednesday expanded an existing agreement with a drug developer that uses artificial intelligence. Novo Nordisk said an agreement reached last year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback